Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis

Posted Nov 17 2009 10:20pm

Fast Forward, LLC and ProvidPharmaceuticals Announce Partnership for Development of PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis

New York, USA and North Brunswick, NJ, May 5, 2009 – Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, today announced a partnership to support Provid’s preclinical studies of PV-267. This novel compound is designed to redirect the abnormal immune response associated with multiple sclerosis (MS).

»Read More



Please return to this page to leave any comments you may have

Post a comment
Write a comment:

Related Searches